Ann: Kazia Investor Presentation, page-13

Agree, I think they planned it that way so there is not a major sell off to buy more shares lower and then convert, as record date is Monday. At 1 for 3 there is little logic in selling for the raise.

This is interesting in that that always talked about bringing in a partner to drive through to commercialisation. I think there engagement with big Pharma and the substantial results from current trials, let alone FDA and the clinical experts, is telling them to hold on through to a different partnering point!

WIth GBM Agile near completion, October 2020, and patient recruitment starting this year this large sum of money should see them through to 2022, where wed have a substantial amount of confidence in the drug(most things going well) and I hope we keep some material level of involvement ongoing.

Ill be going for the full allocation on this one. This gives us a smaller dilution, shares going to loyal shareholders and we know whats coming in the next year.

Pretty exciting times here...